ProKidney Corp. has released its financial results for the third quarter of 2026, revealing key insights into the company's performance and strategic direction. This announcement is significant as it highlights the company's growth trajectory within the biological products industry, a sector characterized by rapid advancements and competitive dynamics.

According to the recent SEC filing, dated November 12, 2026, ProKidney Corp. operates under the Standard Industrial Classification (SIC) code 2836, which pertains to biological products (no diagnostic substances). The company is listed on the Nasdaq under the ticker symbol PROK.

The filing details that on November 12, 2026, ProKidney issued a press release announcing its financial results for the quarter ending September 30, 2026. The press release, which is included as Exhibit 99.1, outlines the company's operational achievements and financial condition.

The announcement is expected to affect various stakeholders, including investors and competitors within the biological products sector. The financial results may influence investor sentiment and market positioning as ProKidney continues to navigate the competitive landscape.

Looking ahead, the filing does not specify any immediate next steps following this announcement. However, the company’s ongoing commitment to transparency and regular updates suggests that further developments may be forthcoming.

Company Overview and Background

ProKidney Corp. was previously known as Social Capital Suvretta Holdings Corp. III until its name change on March 10, 2021. The company is incorporated in Delaware and operates primarily in the biological products sector, focusing on innovative solutions that do not involve diagnostic substances.

Contact Information

ProKidney's principal executive offices are located at 2000 Frontis Plaza Blvd., Suite 250, Winston-Salem, North Carolina, 27103. The company can be reached at the business phone number 336-999-7028.

Exhibits and Additional Information

The SEC filing includes Exhibit 99.1, which contains the detailed press release regarding ProKidney's financial results. This document provides further insights into the company's operational performance and strategic initiatives during the third quarter of 2026.

The filing does not include specific financial figures or detailed performance metrics for the quarter, which would provide a clearer picture of ProKidney's financial health and operational efficiency.